自体T1 mapping作为自身免疫性胰腺炎定量结局替代指标的研究
这项前瞻性研究纳入39例自身免疫性胰腺炎(AIP)患者和40例无胰腺疾病对照,用胰腺MRI自体T1 mapping在糖皮质激素治疗前及治疗中测量T1弛豫时间。AIP组T1弛豫时间较正常胰腺组织显著延长,短期和中期治疗后逐步缩短趋于正常,且与血清IgG4水平呈正相关。作者结论认为自体T1 mapping可用于评估AIP实质炎症并量化治疗反应,提供定量结局替代指标。
要点
- AIP患者胰腺自体T1弛豫时间较正常胰腺组织显著延长,治疗后缩短并趋于正常。
- 在基线血清IgG4升高的AIP患者中,T1弛豫时间与血清IgG4水平呈正相关。
- 在基线血清IgG4正常的AIP患者中,T1弛豫时间缩短早于或与症状缓解一致。
核心结论
- 自体T1 mapping可用于评估AIP的胰腺实质炎症并量化治疗反应,为AIP提供定量结局替代指标。
研究设计与样本
- 前瞻性研究,经机构审查委员会批准,所有患者提供书面知情同意。
- 纳入39例AIP患者,在糖皮质激素治疗前及治疗中行胰腺MRI(含自体T1 mapping),并纳入40例无胰腺疾病患者作为对照。
- 测量每位患者胰腺头、体、尾的T1弛豫时间,并记录患者临床症状和血清IgG4水平。
关键影像表现/征象
- AIP胰腺实质炎症导致T1弛豫时间延长,有效治疗后缩短。
诊断标准与关键数值
- AIP自体T1弛豫时间为1124.5 ms ± 95.7 ms,正常胰腺组织为784.3 ms ± 41.8 ms,AIP较正常显著延长(p < 0.001)。
- 短期糖皮质激素治疗(4周)后AIP T1弛豫时间缩短至957.2 ms ± 97.3 ms(p < 0.001)。
- 中期糖皮质激素治疗(12周)后AIP T1弛豫时间进一步缩短至844.2 ms ± 71.6 ms,趋于正常(p < 0.001)。
- 33例基线血清IgG4升高的AIP患者中,T1弛豫时间与血清IgG4水平呈显著正相关(r = 0.329,p = 0.011)。
临床应用与阅片要点
- 胰腺MRI自体T1 mapping可定量评估AIP胰腺实质炎症并量化对糖皮质激素治疗的反应。
- 在基线血清IgG4正常的6例AIP患者中,T1弛豫时间缩短早于或与症状缓解一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the ability of T1 mapping to visualize and quantify the short-term and mid-term response of autoimmune pancreatitis (AIP) to corticosteroid treatment (CST) and to correlate T1 relaxation time of the pancreas with clinical status and serum IgG4 level.
METHODS: The institutional review board approved this prospective study, and all patients provided written informed consent. Pancreatic MRI including native T1 mapping was performed in 39 AIP patients before and during CST, and 40 patients without pancreatic diseases served as control. T1 relaxation time of the pancreatic head, body, and tail was measured in each patient. Clinical symptoms and serum IgG4 level of the patients were recorded.
RESULTS: The native T1 relaxation time of AIP was significantly elongated compared to normal pancreatic tissue (1124.5 ms ± 95.7 ms vs 784.3 ms ± 41.8 ms, p < 0.001). After short-term CST (4 weeks), T1 relaxation time of AIP already shortened significantly (957.2 ms ± 97.3 ms, p < 0.001). After mid-term CST (12 weeks), the T1 relaxation time further shortened towards normalization (844.2 ms ± 71.6 ms, p < 0.001). In 33 AIP patients with elevated serum IgG4 at baseline, T1 relaxation time demonstrated a significant positive correlation with serum IgG4 level (r = 0.329, p = 0.011). In six AIP patients with normal serum IgG4 level at baseline, T1 relaxation time shortening preceded or was in accordance with symptom relief.
CONCLUSIONS: Native T1 mapping can be used to assess parenchymal inflammation of AIP and to quantify response to treatment. It provides a quantitative outcome surrogate for AIP.
KEY POINTS: • Parenchymal inflammation in autoimmune pancreatitis results in T1 relaxation time elongation, which shortens after effective treatment. • T1 relaxation time of the pancreas correlates with serum IgG4 level, and in serum IgG4-negative AIP patients, T1 relaxation time shortening predicts clinical improvement. • T1 mapping provides a quantitative outcome surrogate for AIP.
引用
- Zhu L, Lai Y, Makowski M, et al. Native T1 mapping of autoimmune pancreatitis as a quantitative outcome surrogate. Eur Radiol. 2019. PMID: 30707275. doi:10.1007/s00330-018-5987-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。